Epidemiology and Biostatistics Seminar Series welcomes Ming-Wen An, professor in the Department of Mathematics and Statistics at Vassar College. Dr. An will present "Alternative Tumor Measurement-based Phase II Clinical Trial Endpoints for Predicting Overall Survival, using the RECIST 1.1 data warehouse". The work she’ll be presenting is in collaboration with the Cancer Center Statistics group in the Division of Biomedical Statistics and Informatics at the Mayo Clinic.

 

In oncology, the high failure rate of Phase III trials could possibly be due to inappropriate evaluation of compounds in preceding Phase II trials, in which the primary endpoint is often binary tumor response measured by the Response Evaluation Criteria for Solid Tumors (RECIST).  We evaluate alternative categorical and continuous tumor measurement (TM)-based endpoints for their ability to predict overall survival (OS) using the RECIST 1.1 data warehouse.  Absolute and relative change in TMs demonstrate potential, but not convincing, improvements in predicting OS compared to RECIST tumor response.